Skip to main content
Equibles
IMRX logo

IMRX · Immuneering Corp

Track IMRX — free

Use IMRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IMRX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.21 +0.15 (+2.96%) At close · Aug 17
Market Cap
$337.72M
Shares
64.70M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.06 Open$5.18 Day$4.93–5.18 52W close$3.04–9.26 Avg vol 30d794K Short int15.4M · 23.8% float · 20.4d Short vol48% Last earningsJun 1, 2026 DataJul 2021–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Dec 19, 2026 Est · unconfirmed · in 18 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg +10%
above
RSI (14) 61
neutral
MACD trend Positive
52-week position 32%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +9%
trailing
6-month return +2%
trailing
YTD return −23%
this year
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+17% holders QoQ · +37 funds added
Insider flow Accumulating
Net +$36.0K over 90 days · 0% sells
Short interest Rising
23.81% of float · ▲ +1.3% MoM · 20.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
111 holders — near 3-yr high, broad support
Squeeze score 87
high risk · 0–100
Fundamentals
Fair
Revenue growth −100%
Y/Y
EPS growth +38%
Y/Y
Free cash flow $-45.5M
Balance sheet $128.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 103%
annualized · 1-yr
Max drawdown −58%
past year
ATR 5.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
+10% Bullish
RSI (14)
61 Neutral
MACD trend
Positive Bullish
52-week position
32% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+17% holders QoQ · +37 funds added
Insider flow Accumulating
Net +$36.0K over 90 days · 0% sells
Short interest Rising
23.81% of float · ▲ +1.3% MoM · 20.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
111 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $5 · 32% Range high $9
vs 200-day avg -6% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and marketable securities $182.7M as of June 30, 2026 —
Patients weight stable or gained weight at 3 months 84% Phase 2a data presented at ASCO 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IMRX
Immuneering Corp
this stock
$337.72M -23.1% -100.0% — 23.8%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +17.5% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
111
% held
54.2%
Net QoQ
+5.4M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
40
View
Short & Settlement
Short Interest Rising
Shares short
15.4M
Days to cover
20.4d
Change
+192.9K sh
View
Short Volume
Short vol %
48%
As of
Aug 17, 2026
Short Total
View
Fails to Deliver
FTD shares
5.5K
Value
$23.3K
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
36.4%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$36.0K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-56.0M
EPS diluted
$-1.27
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
11
View
Proposed Sales
Value
$136.1K
Shares
14.0K
Filed
Sep 23, 2025
View
Exempt Offerings
Offering
$25.0M
Filed
Sep 9, 2025
View
Earnings & Events
Earnings Calls
Last call
Jun 1, 2026
View

Performance

5D 20D 120D MTD YTD
IMRX +12.2% +9.1% +2.0% +22.5% -23.1%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +11.8% +4.6% -11.8% +18.6% -37.0%
Key facts CIK 1790340 CUSIP 45254E107 13F (30d) 107 filings 106 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)